The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The metabolism of Paricalcitol can be increased when combined with Nevirapine. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The metabolism of Paricalcitol can be decreased when combined with Clemastine. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. Paricalcitol may increase the arrhythmogenic activities of Ouabain. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. Danazol may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The metabolism of Paricalcitol can be increased when combined with Primidone. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. Indapamide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The metabolism of Paricalcitol can be increased when combined with Rifampicin. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. Metolazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The metabolism of Paricalcitol can be decreased when combined with Bortezomib.